Next Article in Journal
Crossing the Border: Molecular Control of Motor Axon Exit
Next Article in Special Issue
Loop-Mediated Amplification Accelerated by Stem Primers
Previous Article in Journal
Caffeine Abolishes the Ultraviolet-Induced REV3 Translesion Replication Pathway in Mouse Cells
Previous Article in Special Issue
Applications of Next-Generation Sequencing Technologies to Diagnostic Virology
Article

Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer

1
ViennaLab Diagnostics GmbH, 1120 Vienna, Austria
2
Molecular Oncology Group, Department of Obstetrics and Gynecology, Medical University Vienna, 1090 Vienna, Austria
3
Ludwig Boltzmann Gesellschaft, Cluster Translational Oncology, 1090 Vienna, Austria
4
Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria
5
Department of Cardiothoracic Surgery, Medical University of Vienna, 1090 Vienna, Austria
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2011, 12(12), 8530-8538; https://doi.org/10.3390/ijms12128530
Received: 18 September 2011 / Revised: 17 November 2011 / Accepted: 17 November 2011 / Published: 29 November 2011
(This article belongs to the Special Issue Advances in Molecular Diagnostics)
This study is aimed at evaluating the potential of a biochip assay to sensitively detect KRAS mutation in DNA from non-small cell lung cancer (NSCLC) tissue samples. The assay covers 10 mutations in codons 12 and 13 of the KRAS gene, and is based on mutant-enriched PCR followed by reverse-hybridization of biotinylated amplification products to an array of sequence-specific probes immobilized on the tip of a rectangular plastic stick (biochip). Biochip hybridization identified 17 (21%) samples to carry a KRAS mutation of which 16 (33%) were adenocarcinomas and 1 (3%) was a squamous cell carcinoma. All mutations were confirmed by DNA sequencing. Using 10 ng of starting DNA, the biochip assay demonstrated a detection limit of 1% mutant sequence in a background of wild-type DNA. Our results suggest that the biochip assay is a sensitive alternative to protocols currently in use for KRAS mutation testing on limited quantity samples. View Full-Text
Keywords: non-small cell lung cancer; KRAS; mutation detection; biochip hybridization non-small cell lung cancer; KRAS; mutation detection; biochip hybridization
Show Figures

MDPI and ACS Style

Kriegshäuser, G.; Fabjani, G.; Ziegler, B.; Zöchbauer-Müller, S.; End, A.; Zeillinger, R. Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer. Int. J. Mol. Sci. 2011, 12, 8530-8538. https://doi.org/10.3390/ijms12128530

AMA Style

Kriegshäuser G, Fabjani G, Ziegler B, Zöchbauer-Müller S, End A, Zeillinger R. Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 2011; 12(12):8530-8538. https://doi.org/10.3390/ijms12128530

Chicago/Turabian Style

Kriegshäuser, Gernot, Gerhild Fabjani, Barbara Ziegler, Sabine Zöchbauer-Müller, Adelheid End, and Robert Zeillinger. 2011. "Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer" International Journal of Molecular Sciences 12, no. 12: 8530-8538. https://doi.org/10.3390/ijms12128530

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop